Medicare Part D Application for New PACE Organizations 2010 Contract Year

Public Reporting Burden

According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for information collection contained in this chapter is 0938-0936. The time required to complete this information collection is estimated to average 15 hours per response, including the time to review instructions, search existing data resources, gather the data needed, and complete and review the information collection. If you have any comments concerning the accuracy of the time estimate(s) or suggestions for improving this form, please write to: CMS, 7500 Security Boulevard, C4-26-05, Baltimore, Maryland 21244-1850.

I. GENERAL INFORMATION (§423.1- §423.910)

Background

The Medicare Prescription Drug Benefit program was established by section 101 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) and is codified in section 1860D-1 through 1860 D-42 of the Social Security Act (the Act). Section 101 of the MMA amended Title XVIII of the Social Security Act by redesignating Part D as Part E and inserting a new Part D, which establishes the Voluntary Prescription Drug Benefit Program (hereinafter referred to as "Part D").

<u>Overview</u>

The Part D benefit constitutes perhaps the most significant change to the Medicare program since its inception in 1965 by recognizing the vital role of prescription drugs in our health care delivery system. However, PACE organizations have a longstanding history of providing statutorily required prescription drugs to all participants. Prior to Part D, prescription drugs were included as a portion of the Medicaid capitation rate. However, the MMA mandates that State Medicaid programs may no longer cover Part D drugs on behalf of dual eligible beneficiaries. PACE organizations may elect to offer a Part D plan in a similar manner as MA-PD local plans in order to account for this shift in payer source for prescription drugs.

This chapter of the PACE provider application serves as the Medicare Part D application.

NOTE: CMS reserves the right to amend or cancel this solicitation at any time. CMS also reserves the right to revise the Medicare Prescription Drug Benefit program implementation schedule, including the solicitation and bidding process timelines.

Summary of PACE Organization's Roles and Responsibilities

Each PACE Organization should have the ability to:

- Submit a formulary each year for CMS approval (as applicable).
- Submit a Part D bid each year for CMS approval.
- Administer the Part D benefit.
- Provide all required prescription drug services as outlined in the PACE statute and regulation.
- Operate quality assurance, drug utilization review, and medication therapy management programs in accordance with existing PACE requirements.
- Protect the privacy of beneficiaries and beneficiary-specific health information.
- Develop and/or maintain systems to support enrollment, provide claims-based data to CMS, accept CMS payment, and support e-prescribing.
- Provide necessary data to CMS to support payment, oversight, and quality improvement activities and otherwise cooperate with CMS oversight responsibilities.
- Ensure the integrity of the Medicare Trust Fund by eliminating fraud, abuse, and waste within its organization.

Health Plan Management System (HPMS)

Completion of the CMS PACE Provider Application and the Part D application (chapter 11) is a significant step towards attaining CMS approval to provide the Part D benefit to eligible PACE participants. In addition, PACE organizations are required to secure access to the CMS Health Plan Management System (HPMS) in order to carry out additional Part D functions including the formulary submission process (as applicable), the bid submission process, ongoing operations of the Part D program, and reporting and oversight activities.

PACE organizations must obtain HPMS user ID's and access to the system only after being assigned a CMS provider number or "H-number". PACE organizations are assigned CMS "H-numbers" upon CMS receipt of the PACE provider application. We note that the PACE provider application is routed to CMS only after it has been reviewed by the SAA. Once your application has arrived and CMS assigns an "H-number, you will be notified by your CMS PACE team lead. At this point, the PACE organizations staff must obtain HPMS user ID's in order to access the system. The HPMS user ID application may be accessed at:

http://www.cms.hhs.gov/AccesstoDataApplication/Downloads/Access.pdf

In addition, instructions to PACE organization for completing this form are located at: http://www.cms.hhs.gov/pace/hpmsconn.pdf

Questions concerning HPMS user IDs should be directed to the HPMS Help Desk at helpdesk@hpms@cms.hhs.gov

Summary Instruction for Part D Formularies (423.120)

Applicants that meet one or more of the definitive criteria for formularies described later in this document will be required to upload their plan formularies to HPMS using a pre-defined file format and record layout.

Summary Instruction for Part D Bids (423.265)

Each PACE applicant must submit to CMS, via HPMS, two Part D bids; 1 for dual eligible enrollees and 1 for Medicare-only enrollees. Applicants using this solicitation must apply to offer full risk Part D plans.

The applicants bid will represent the expected monthly cost to be incurred by the applicant for qualified prescription drug coverage in the plan's service area for a Part D-eligible beneficiary on a standardized basis. The costs represented in each bid should be those for which the applicant would be responsible. The bid will require the separate identification, calculation, and reporting of costs assumed to be reimbursed by CMS through reinsurance. CMS requires that the bid represent a uniform benefit package among all beneficiaries enrolled in the plan. The benefit packages submitted must be cross walked appropriately from the formulary (as applicable). Pursuant to 423.505(k)(4), the CEO, CFO, or a delegee with the authority to sign on behalf of one of these officers, and who reports directly to such officer, must certify (based on best knowledge, information and belief) that the information in the bid submission is accurate, complete, and truthful, and fully conforms to the requirements in section 423.265 of the regulations (except section 423.265(b), the applicability of which is discussed below). In addition, the pricing component of the bid must be certified by a qualified actuary.

PACE organizations must submit annual Part D bids and receive CMS approval of the Part D bids prior to providing or continuing to provide Part D benefits. Any PACE organization that wishes to either continue receiving Part D payment or begin receiving Part D payment in January of a given year, must submit their Part D bids no later than the first Monday in June of the year prior. The June bid submission deadline (423.265(b)) has been waived for newly forming PACE organizations pending the development of a methodology for accepting mid-year bids.

In order to prepare plan bids, Applicants will use HPMS to define their plan structures and associated plan service areas and then download the Plan Benefit Package (PBP) and Bid Pricing Tool (BPT) software. For each plan being offered, Applicants will use the PBP software to describe the detailed structure of their Part D benefit and the BPT software to define their bid pricing information. The formulary (as applicable) must accurately crosswalk to the PBP.

Once the PBP and BPT software has been completed for each plan being offered, Applicants will upload their bids to HPMS.

CMS Review of Part D Bids

CMS will evaluate the bids based on four broad areas: 1) administrative costs, 2) aggregate costs, 3) benefit structure, and 4) plan management. CMS will evaluate the administrative costs for reasonableness in comparison to other PACE bidders. CMS will also examine aggregate costs to determine whether the revenue requirements for qualified prescription drug coverage

are reasonable and equitable. In addition, CMS will review the steps the PACE Part D sponsor is taking to control costs, such as through various programs to encourage use of generic drugs. Finally, CMS will examine indicators concerning plan management.

CMS is also required to make certain that bids and plan designs meet statutory and regulatory requirements. We will conduct an actuarial analysis to determine whether the proposed benefit meets the standard of providing qualified prescription drug coverage.

Overview of Part D Bid Negotiation

CMS evaluates the reasonableness of bids submitted by PACE Part D sponsors by means of an actuarial valuation analysis. This requires evaluating assumptions regarding the expected distribution of costs, including average utilization and cost by drug coverage tier. CMS could test these assumptions for reasonableness through actuarial analysis and comparison to industry standards and other comparable bids. Bid negotiation could take the form of negotiating changes upward or downward in the utilization and cost per script assumptions underlying the bid's actuarial basis. We could exercise our authority to deny a bid if we do not believe that the bid and its underlying drug prices reflect market rates.

Standard Contract with PACE Part D Sponsors

Successful Applicants will be deemed qualified to enter into a PACE program agreement that includes Part D coverage. Under this agreement the PACE Part D sponsor will be authorized to operate the Medicare Part D benefit for all eligible PACE participants. Only after the qualified Applicant and CMS have reached agreement on the Applicant's bid submissions will the Applicant be asked to execute its PACE program agreement.

General Enrollment Processing

CMS has developed a system to review an individual's eligibility for the Part D benefit. For individuals applying for enrollment in a Part D plan, CMS reviews an individual's status as a Medicare beneficiary. CMS tracks enrollments and ensures that the beneficiary does not enroll in more than one plan. Also, CMS tracks low-income subsidy status and auto-enrollments of full-benefit dual eligible individuals into Part D plans and facilitated enrollments for other low-income Medicare beneficiaries. Finally, CMS tracks dis-enrollments from Part D plans and will deny new enrollments during any given year unless the enrollment occurs during an allowable enrollment period. For additional information regarding enrollment processing, refer to the www.cms.hhs.gov website.

Eligibility for the Low Income Subsidy Program

Low-income Medicare beneficiaries receive full or partial subsidies of premiums and reductions in cost sharing under the Part D benefit. Certain groups of Medicare beneficiaries are automatically be eligible for the low-income subsidy program. These beneficiaries include Medicare beneficiaries who are full-benefit dual eligible individuals (eligible for full benefits under Medicaid), Medicare beneficiaries who are recipients of Supplemental Security Income benefits; and participants in Medicare Savings Programs as Qualified Medicare Beneficiaries (QMBs), Specific Low-Income Medicare Beneficiaries (SLMBs), and Qualifying Individuals (QIs). Beneficiaries who are low-income and who do not fall into one of the automatic subsidy eligibility groups apply for a low-income subsidy and have their eligibility determined by either the state in which they reside or the Social Security Administration (SSA). CMS has developed a database to track individuals who are automatically deemed subsidy-eligible or who are determined subsidy-eligible by states or SSA, and communicates the names and eligibility category of those individuals to Part D sponsors as part of the enrollment files from the enrollment processing system described below. For additional information regarding the low income subsidy program, refer to the <u>www.cms.hhs.gov/</u> website.

Protection of Confidential Information

Applicants may seek to protect their information from disclosure under the Freedom of Information Act (FOIA) by claiming that FOIA Exemption 4 applies. The Applicant is required to label the information in question "confidential" or "proprietary", and explain the applicability of the FOIA exemption it is claiming. This designation must be in writing. When there is a request for information that is designated by the Applicant as confidential or that could reasonably be considered exempt under Exemption 4, CMS is required by its FOIA regulation at 45 C.F.R. §5.65(d) and by Executive Order 12,600 to give the submitter notice before the information is disclosed. To decide whether the Applicant's information is protected by Exemption 4, CMS must determine whether the Applicant has shown that— (1) disclosure of the information might to impair the government's ability to obtain necessary information in the future; (2) disclosure of the information would cause substantial harm to the competitive position of the submitter; (3) disclosure would impair other government interests, such as program effectiveness and compliance; or (4) disclosure would impair other private interests, such as an interest in controlling availability of intrinsically valuable records, which are sold in the market. Consistent with our approach under the Medicare Advantage program, we would not release information under the Medicare Part D program that would be considered proprietary in nature.

Payment to PACE Part D Sponsors

Payments will be wired to the organization's account on the first business day of each month (or the last business day of the prior month if the first day of the month is not a business day). The monthly payment will include premiums that SSA or other agencies are deducting from beneficiary Social Security payments or other payments as well as those premiums CMS is paying on behalf of low-income individuals. Estimated monthly reinsurance subsidies, and low-income subsidies are also included.

Applicability of the National Provider Identifier (NPI) to PACE Organizations

The Administrative Simplification provisions of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) mandated the adoption of standard unique identifiers for health care providers, as well as the adoption of standard unique identifiers for health plans. The purpose of these provisions is to improve the efficiency and effectiveness of the electronic transmission of health information. The NPI has been adopted as the standard unique identifier for health care providers. The National Plan and Provider Enumeration System (NPPES) is the entity that assigns these unique identifiers.

For purposes of HIPAA, PACE organizations may be defined as both health plans and health care providers. We note that an enumeration system applicable to health plans is still in the development stages. However, any health care provider, as that term is defined for purposes of HIPAA that transmits any health information in electronic form in connection with one of the standard transactions, including electronically billing any health plan (including Medicare), must obtain an NPI. Health care providers are defined at 45 CFR §160.103 as "a provider of services (as defined in section 1861 (u) of the Act, 42 USC 1395x (u)), a provider of medical or health services (as defined in section 1861(s) of the Act, 42 ISC 1395x(s)), and any other person or organization who furnishes, bills, or is paid for health care in the normal course of business."

Although PACE organizations may meet the definition or a health care provider, as described above, only those that transmit health information in electronic form in connection with one of the standard transactions, including billing any health plan electronically must obtain an NPI.

We note that in some instances, PACE organizations may elect to provide Medicare services to a beneficiary prior to the beneficiary's effective date of PACE enrollment. These services may be billable under Medicare Fee-For-Service. To the extent a PACE organization that is a HIPAA health care provider elects to bill Medicare electronically for these non-PACE services, an NPI would be needed.

In addition, consistent with HIPAA requirements, as health plans, all PACE organizations (regardless of whether the NPI requirements apply to them as health care providers) are required to accept and recognize the NPI as the health care provider identifier in standard transactions that are submitted to them from health care providers or other health plans.

II. GENERAL INSTRUCTIONS

Summary Instructions and Technical Support

This application is to be completed by those newly forming PACE organizations that intend to provide the Part D benefit to eligible participants beginning in 2010. Applicants projecting PACE provider status by 1/1/2010 may submit the Part D application (chapter 11 of the PACE provider application) up until July 1, 2009. Applicants must use the 2010 solicitation. CMS will not accept or review in any way those submissions using prior version of the application.

For technical assistance in the completion of this application, contact: Eric Nevins by email at: eric.nevins@cms.hhs.gov or by phone at 410-786-1162.

Instructions

Applicants must include the name of the PACE organization in the heading on each page of the Part D application submitted to CMS.

In many instances Applicants are directed to affirm that they will meet particular requirements by indicating "Yes" next to a statement of a particular Part D program requirement. By providing such attestation, an Applicant is committing its organization to complying with the relevant requirements as of the date your contract is signed, unless an alternative date is noted.

Additional supporting documentation is notated in the following manner throughout the application and is to be submitted as follows:

Forms: documents supplied by CMS that are contained at the end of this application. They are to be completed by the Applicant and returned to CMS as indicated.

Legal documents such as subcontracts should be provided in hard copy as an attachment to the application. In addition, all subcontracts and other legal documents should be provided on the CD or diskette copies of the application. The CD/diskette identification should include the form number.

CMS will check the Part D application for completeness shortly after its receipt. We will notify Applicants of any deficiencies and afford them the opportunity to amend their Part D applications.

CMS may verify a sponsor's compliance with qualifications it attests it will meet, through on-site facility visits as well as through other program monitoring techniques.

Failure to meet the requirements attested to in the Applicant's response to this solicitation and failure to operate its Part D plan(s) consistent with the requirements of the applicable statutes, regulations, and the Part D contract may disqualify it from participation in the Part D program.

An individual with legal authority to bind the Applicant shall sign and submit the certification. CMS reserves the right to request clarifications or corrections to a submitted application. Failure to provide requested clarifications could result in the applicant receiving a notice of intent to deny the application, in which case, the Applicant will then have 10 days to seek to remedy its application.

This solicitation does not commit CMS to pay any cost for the preparation and submission of a Part D application.

Format

- All responses should be completed in Microsoft Word (in a version that is compatible with Office 2003). Attachments (such as existing contracts) can be submitted in Microsoft Word (in a version that is compatible with Windows 2003) or as a PDF file.
- At the time you receive notification from CMS that your provider application has been received from the State, you must submit a cover letter and six (5) hard copies of the Part D application (Chapter 11) and supporting documentation to CMS. In addition, the applicant should simultaneously submit one copy to the State Administrating Agency (SAA).

Centers for Medicare & Medicaid Services (CMS) Eric Nevins Mail Stop: C4-21-08 Attn: PACE Part D Application 7500 Security Boulevard Baltimore, Maryland 21244-1850

- Each hard copy of the Part D application should include tab indexing identifying all of the major sections of the Part D application. Page size should be 8 ½ by 11 inches. Font size should be 12 point.
- One Part D application should be clearly marked, "Original" and contain all original signed certifications requested in the application. Note: It is important that Applicant provide 2 separate contact persons and applicable contact information for PACE organization Application submission(s). This will help to avoid delays in the processing of an application.
- Along with five paper copies of the Part D application each applicant must submit five (5) duplicate CDs or diskettes. This will support the review of the application by different CMS components.
- Each CD or diskette must be clearly labeled with the information in the table below:

Applicant's Organization Name

CD or Diskette Number (Copy 1, Copy 2, Copy 3, etc.)

Note: If multiple CDs or diskettes are required to include written application, appendices, attachments and other supporting documentation, label as follows: Copy 1 (1 of 2), Copy 1 (2 of 2), Copy 2 (1 of 2), Copy 2 (2 of 2), etc.

- In order for CMS to receive your application in a timely manner, please note that Federal Express and the US Postal Service possess a CMS security clearance. Applications mailed through carriers that do not have CMS Security Clearance could be delayed due to clearance processing.
- Failure to submit a Part D application consistent with these instructions may delay its review by CMS and could result in receipt of a notice of intent to deny.

Bid and formulary (as applicable) submissions are required on an annual basis. Although CMS will not require resubmission of this chapter on an annual basis, we expect to be notified of any changes to responses initially provided.

III. INSTRUCTIONS FOR COMPLETION OF GENERAL APPLICATION REQUIREMENTS

The following section provides instructions for completing this chapter of the application. The actual application forms are included under section IV.

Note: Nothing in this chapter of the PACE Provider Application is intended to supersede the regulations at 42 CFR Part 423 or Part 460. Failure to reference a regulatory requirement in this application does not affect the applicability of such requirement, and PACE Organizations are required to comply with all applicable requirements of the regulations in Part 423 or Part 460 of 42 CFR.

PART D WAIVERS

CMS is authorized to grant waivers of Part D program requirements where such a requirement conflicts with or duplicates a PACE requirement, or where granting such a waiver would improve the PACE Organization's coordination of PACE and Part D benefits. The following waivers are in effect for all PACE organizations.

Part D Regulation	Regulatory Requirement(s)
	Description
423.44	Involuntary disenrollment
423.48	Information about Part D
423.50	Approval of marketing materials and enrollment forms
423.104(g)(1)	Access to negotiated prices
423.112	Establishment of PDP service areas
423.120(a)	Access to covered Part D drugs
423.120(c)	Use of standardized technology
423.124	Out-of-network access to covered Part D drugs at out-of-network
	pharmacies
423.128	Dissemination of Part D plan information
423.132	Public disclosure of pharmaceutical prices for equivalent drugs
423.136	Privacy, confidentiality, and accuracy of enrollee records
423.153(a)-423.153(d)	Drug utilization management, quality assurance, and medication
	therapy management programs (MTMPs)
423.156	Consumer satisfaction surveys
423.162	Quality Improvement organization activities
423.265(b)	Part D bid submission deadline
Note: Automatic waiver applies to new or potential	
organizations that are not operational by the June deadline.	
Those organizations with effective program agreements	
must submit a Part D waiver request in the event they are	
unable to meet the June deadline.	
423.401(a)(1)	Licensure
423.420	Solvency standards for non-licensed entities

Summary of Medicare Part D Regulatory Requirements Waived for PACE Organizations

Part D Regulation	Regulatory Requirement(s)
	Description
423.462	Medicare secondary payer procedures
423.464(c)	Coordination of benefits and user fees
423.464(f)(2) and 423.464(f)(4)	Coordination with other prescription drug coverage
423.502(b)(1)(i-ii)	Documentation of State licensure or Federal waiver
423.504(b)(2-3), 423.504(b)(4)(i-v) and (vi)(A-E), and 423.504(d)	Conditions necessary to contract as a Part D plan sponsor
Note: Organizations are required to abide by	
423.504(b)(4)(vi)(F-H), 423.504(b)(5), 423.504(c), and	
423.504(e)	
423.505(a-c) and 423.505(e-i)	Contract provisions
Note: Organizations are required to abide by 423.505(d and j)	
423.505(k)(6)	Certification for purposes of price compare
Note: Organizations are required to abide by 423.505(k)(1-5)	
423.506(a)-(b)	Effective date and term of contract
Note: Organizations are required to abide by 423.506(c)-(e)	
423.512 – 423.514	Contracting terms
423.551-423.552	Change of ownership or leasing of facilities during term of
	contract
423.560-423.638	Grievances, coverage determinations, and appeals
N/A	A PDP sponsor is required to be a nongovernmental entity

Applicant Requests for Additional Waivers:

CMS may grant additional waivers upon a PACE Organization's request, provided that the waivers may be justified because the Part D requirement is duplicative of or conflicting with PACE requirements, or the waiver will improve the coordination of PACE and Part D benefits. Any waiver granted by CMS will apply to all similarly situated PACE Organizations.

PACE Organizations that identify the need for additional Part D waivers must submit a separate Part D waiver request package that includes:

- 1. The Part D regulation reference;
- 2. The appropriate waiver criteria (e.g. duplicative, conflicts, improves benefit coordination);
- 3. A discussion of how the requested waiver meets at least one of the three waiver criteria.

Four copies of these requests should be submitted to the following address:

Centers for Medicare and Medicaid Services (CMS) Janet Samen Attn: Part D PACE Waiver Request Mail Stop: C5-05-27 7500 Security Boulevard Baltimore, MD 21244-1850

Finally, the PACE Organization should also copy their State Administering Agency on the request as well as their CMS PACE Team Lead.

Determinations will be coordinated between Part D and PACE policy staff and issued to applicants following a comprehensive review of the request in a similar manner as PACE BIPA 903 waivers are evaluated in accordance with sections 460.26(b) and 460.28 of the PACE regulation.

IV. APPLICATION FORMS

Please do not submit the previous pages of this chapter in the printed copy of your application.

CENTERS FOR MEDICARE AND MEDICAID SERVICES MEDICARE PART D APPLICATION PROGRAM OF ALL-INCLUSIVE CARE FOR THE ELDERLY (PACE)

NAME OF LEGAL ENTITY	MAILING ADDRESS
TRADE NAME (if different)	
PARENT ORGANIZATION (if applicable)	
AREA CODE TELEPHONE NO. EXTENSION	FAX
CEO OR EXECUTIVE DIRECTOR: NAME AND TITLE	MAILING ADDRESS
TELEPHONE NUMBER	
PRIMARY APPLICANT CONTACT PERSON: NAME TITLE ADDRESS	
E-MAIL FAX TELEPHONE NUMBER	

SECONDARY APPLICANT CONTACT PERSON: NAME TITLE ADDRESS	
E-MAIL FAX TELEPHONE NUMBER	

Management and Operations

Provide the names of the Part D subcontractors (first	Function	Subcontractor(s) (first tier, downstream and related entities)
tier, downstream and related entities) you will use to carry out each of the functions	A pharmacy benefit program that performs adjudication and processing of pharmacy claims at the point of sale.	
listed in this chart: (Indicate "APPLICANT" where	A pharmacy benefit program that performs negotiation with prescription drug	
applicant will perform those functions)	manufacturers and others for rebates, discounts, or other price concessions on prescription drugs	
	A pharmacy benefit program that performs administration and tracking of enrollees' drug benefits in real time.	
	A pharmacy benefit program that performs coordination with other drug benefit	
	programs, including, for example, Medicaid, state pharmaceutical assistance programs, or other insurance.	
	Develops and maintains a pharmacy network.	
	A pharmacy benefit program that operates an enrollee grievance and appeals process	
	A pharmacy benefit program that performs customer service functionality, that includes serving seniors and	
	persons with a disability. A pharmacy benefit program that performs pharmacy technical assistance service	
	A pharmacy benefit program that performs pharmacy	

Subcontractor (first tier, downstream and related entities) Function Chart

PACE organizations	
functioning with formularies	
agree to maintain	
pharmaceutical and	
therapeutic committees.	

Provide as attachments copies of executed contracts with each subcontractor (first tier, downstream and related entities) identified in the above table that:

- 1. Clearly identify the parties to the contract (or letter of agreement);
- 2. Describe the functions to be performed by the subcontractor (first tier, downstream and related entities);
- 3. Describe the reporting requirements the subcontractor (first tier, downstream and related entities) has to the Applicant;
- Contain language clearly indicating that the subcontractor (first tier, downstream and related entities) has agreed to participate in your Medicare Prescription Drug Benefit program (except for a network pharmacy if the existing contract would allow participation in this program);
- 5. Contains flow-down clauses requiring their activities be consistent and comply with the Applicant's contractual obligations as a PACE Part D sponsor;
- 6. Describe the payment the subcontractor (first tier, downstream and related entities) will receive for performance under the contract, if applicable;
- 7. Are signed by a representative of each party with legal authority to bind the entity;
- 8. Contain language obligating the subcontractor (first tier, downstream and related entities) to abide by all applicable Federal laws and regulations and CMS instructions;
- Contain language obligating the subcontractor (first tier, downstream and related entities) to abide by State and Federal privacy and security requirements, including the confidentiality and security provisions stated in the regulations for this program at 42 CFR 423.136.

10. Contain language ensuring that the subcontractor (first tier, downstream and related entities) will make its books and other records available in accordance with 42 CFR 423.505(e)(2) and 42 CFR 423.505(i)(2). Generally stated these regulations give HHS, the Comptroller General, or their designees the right to audit, evaluate and inspect any books, contracts, records, including medical records and documentation involving transactions related to CMS' contract with the PACE Part D sponsor and that these rights continue for a period of 10 years from the final date of the contract period or the date of audit completion, whichever is later.

11. Contain language that the subcontractor (first tier, downstream and related entities) will ensure that beneficiaries are not held liable for fees that are the responsibility of the PACE Part D sponsor;

12. Contain language indicating that any books, contracts, records, including medical records and documentation relating to the Part D program will be provided to either the sponsor to provide to CMS or its designees or will be provided directly to CMS or its designees;

13. Contain language that if the Applicant, upon becoming a PACE Part D sponsor, delegates an activity or responsibility to the subcontractor (first tier, downstream and related entities), that such activity or responsibility may be revoked if CMS or the sponsor determines the subcontractor (first tier, downstream and related entities) has not performed satisfactorily. Note: The subcontract may include remedies in lieu of revocation to address this requirement;

14. Contain language specifying that the Applicant, upon becoming a PACE Part D sponsor, will monitor the performance of the (first tier, downstream and related entities) subcontractor on an ongoing basis;

15. If the subcontractor (first tier, downstream and related entities) will establish the pharmacy network or select pharmacies to be included in the network, contain language that the PACE Part D sponsor retains the right to approve, suspend, or terminate any arrangement with a pharmacy.

16. If the subcontractor (first tier, downstream and related entities) will establish the pharmacy network or select pharmacies to be included in the network contain language that payment to such pharmacies (excluding long-term care and mail order) shall be issued, mailed, or otherwise transmitted with respect to all clean claims submitted by or on behalf of pharmacies within 14 days for electronic claims and within 30 days for claims submitted otherwise.

17. If the subcontractor (first tier, downstream and related entities) will establish the pharmacy network or select pharmacies to be included in the network contain language that if a standard is used for reimbursement, the source used by the Part D sponsor for making any such pricing updates and a provision that updates to such a standard occur not less frequently than once every 7 days beginning with an initial update on January 1 of each year, to accurately reflect the market price of acquiring the drug.

Crosswalks of Requirements in Subcontracts

INSTRUCTIONS: Applicants must complete the following chart for each subcontractor submitted Applicants must identify in which contract or addendum and where specifically (i.e., section numbers, page numbers, paragraph numbers, etc.) in each subcontract the following elements are found. [E.g., Medicare Part D Addendum, page 14, section 3.2, paragraph 2.] Requirement Citation The parties to the contract The functions to be performed by the subcontractor (first tier, downstream and related entities). Describes the reporting requirements the subcontractor (first tier, downstream and related entities) has to the Applicant. Language clearly indicating that the subcontractor (first tier, downstream and related entities) has agreed to participate in your Medicare Prescription Drug Benefit program (except for a network pharmacy if the existing contract would allow participation in this program). Contains flow-down clauses requiring the subcontractor's (first tier,

downstream and related entities) activities to be consistent and comply with	
the Applicant's contractual obligations as a Part D sponsor.	
The payment the subcontractor (first tier, downstream and related entities) will	
receive for performance under the contract, if applicable.	
Are for a term of at least the one-year contract period for which application is	
submitted.	
Are signed by a representative of each party with legal authority to bind the	
entity.	
Language obligating the subcontractor (first tier, downstream and related	
entities) to abide by all applicable Federal laws and regulations and CMS	
instructions.	
Language obligating the subcontractor (first tier, downstream and related	
entities) to abide by State and Federal privacy and security requirements,	
including the confidentiality and security provisions stated in the regulations for	
the program at 42 CFR §423.136.	
Contain language ensuring that the subcontractor (first tier, downstream and	
related entities) will make its books and other records available in accordance	
with 42 CFR 423.505(e)(2) and 42 CFR 423.505(i)(2). Generally stated these	
regulations give HHS, the Comptroller General, or their designees the right to	
audit, evaluate and inspect any books, contracts, records, including medical	
records and documentation involving transactions related to CMS' contract with the PACE Part D sponsor and that these rights continue for a period of 10	
years from the final date of the contract period or the date of audit completion,	
whichever is later.	
Language stating that the subcontractor will ensure that beneficiaries are not	
held liable for fees that are the responsibility of the Applicant.	
Contain language indicating that any books, contracts, records, including	
medical records and documentation relating to the Part D program will be	
provided to either the sponsor to provide to CMS or its designees or will be	
provided directly to CMS or its designees.	
Contain language that if the Applicant, upon becoming a PACE Part D	
sponsor, delegates an activity or responsibility to the subcontractor (first tier,	
downstream and related entities), that such activity or responsibility may be	
revoked if CMS or the sponsor determines the subcontractor (first tier,	
downstream and related entities) has not performed satisfactorily. Note: The	
subcontract may include remedies in lieu of revocation to address this	
requirement.	
Language specifying that the Applicant, upon becoming a Part D sponsor, will	
monitor the performance of the subcontractor (first tier, downstream and	
related entities) on an ongoing basis. Language that the Part D sponsor retains the right to approve, suspend, or	
terminate any arrangement with a pharmacy if the subcontractor (first tier,	
downstream and related entities) will establish the pharmacy network or select	
pharmacies to be included in the network.	
Language that if the subcontractor (first tier, downstream and related entities)	
will establish the pharmacy network or select pharmacies to be included in the	
network contain language that payment to such pharmacies (excluding long-	

term care and mail order) shall be issued, mailed, or otherwise transmitted with respect to all clean claims submitted by or on behalf of pharmacies within 14 days for electronic claims and within 30 days for claims submitted otherwise.	
Language that if the subcontractor (first tier, downstream and related entities) will establish the pharmacy network or select pharmacies to be included in the network contain language that if a standard is used for reimbursement, the source used by the Part D sponsor for making any such pricing updates and a provision that updates to such a standard occur not less frequently than once every 7 days beginning with an initial update on January 1 of each year, to accurately reflect the market price of acquiring the drug.	

INSTRUCTIONS: Applicants must complete the following chart (which contains applicable requirements from above AND additional requirements specific to Pharmacy Access) for each Long-Term Care pharmacy contract template submitted. Applicants must identify in which contract or addendum and where specifically (i.e., section numbers, page numbers, paragraph numbers, etc.) in each subcontract the following elements are found. [E.g., Medicare Part D Long-Term Care Pharmacy Addendum, page 14, section 3.2, paragraph 2.]

The provisions listed below must be in all pharmacy contracts. If contracts reference policies and procedures with which the pharmacy must comply, provide the relevant documentation as evidence and cite this documentation accordingly.

Requirement	Citation
The functions to be performed by the subcontractor	
(first tier, downstream and related entities).	
Describes the reporting requirements the	
subcontractor (first tier, downstream and related	
entities) identified in the application has to the	
Applicant. Language obligating the subcontractor (first tier,	
downstream and related entities) to abide by all	
applicable Federal laws and regulations and CMS	
instructions.	
Language obligating the subcontractor (first tier,	
downstream and related entities) to abide by State	
and Federal privacy and security requirements,	
including the confidentiality and security provisions stated in the regulations for the program at 42 CFR	
§423.136.	
Contain language ensuring that the subcontractor	
(first tier, downstream and related entities) will make	
its books and other records available in accordance	
with 42 CFR 423.505(e)(2) and 42 CFR	
423.505(i)(2). Generally stated these regulations	
give HHS, the Comptroller General, or their	
designees the right to audit, evaluate and inspect any books, contracts, records, including medical records	
and documentation involving transactions related to	
CMS' contract with the PACE Part D sponsor and	
that these rights continue for a period of 10 years	
from the final date of the contract period or the date	

of audit completion, whichever is later.	
Language stating that the subcontractor (first tier,	
downstream and related entities) will ensure that	
beneficiaries are not held liable for fees that are the	
responsibility of the Applicant.	
Contain language indicating that any books,	
contracts, records, including medical records and	
documentation relating to the Part D program will be	
provided to either the sponsor to provide to CMS or	
its designees or will be provided directly to CMS or its	
designees.	
Contain language that if the Applicant, upon	
becoming a PACE Part D sponsor, delegates an	
activity or responsibility to the subcontractor (first tier,	
downstream and related entities), that such activity or	
responsibility may be revoked if CMS or the sponsor	
determines the subcontractor (first tier, downstream	
and related entities) has not performed satisfactorily.	
Note: The subcontract may include remedies in lieu	
of revocation to address this requirement.	
Language specifying that the Applicant, upon	
becoming a Part D sponsor, will monitor the	
performance of the subcontractor (first tier,	
downstream and related entities) on an ongoing	
basis.	
Provisions requiring that the long-term care	
pharmacy have not less than 30 days (but not more	
than 90 days) to submit claims to the sponsor for	
reimbursement under the plan.	
For those contracts that use a standard for	
reimbursement, provisions that indicate the source	
used by the Part D sponsor for making any such	
pricing updates and a provision that updates to such	
a standard occur not less frequently than once every	
7 days beginning with an initial update on January 1	
of each year, to accurately reflect the market price of	
acquiring the drug.	
Provisions governing submitting claims to a real-time	
claims adjudication system.	
Note: Applicant may indicate for I/T/U pharmacies	
and for certain pharmacies that are allowed to submit	
claims in the X 12 format that these may be batch	
processed.	
Provisions governing providing Part D enrollees	
access to negotiated prices as defined in 42 CFR	

423.100	
Provisions regarding charging/applying the correct cost-sharing amount.	

Elements Specific to Long-Term Care Contracts

Note: CMS Long-Term Care Guidance included in Chapter 5 of the Prescription Drug Benefit Manual contains an updated list of performance and service criteria for contracting with long-term care pharmacies. Applicants are required to incorporate at a minimum, these criteria in ALL LTC pharmacy network contracts. Applicant must list the criteria below, and then identify where the elements reside in the contract template(s) submitted.

	Performance and Service Criteria	Citation
1.	<i>Comprehensive Inventory and Inventory Capacity</i> – Network Long-Term Care Pharmacies (NLTCPs) must provide a comprehensive inventory of Plan formulary drugs commonly used in the long term care setting. In addition, NLTCPs must provide a secured area for physical storage of drugs, with necessary added security as required by federal and state law for controlled substances. This is not to be interpreted that the pharmacy will have inventory or security measures outside of the normal business setting.	
2.	Pharmacy Operations and Prescription Orders NLTCPs must provide services of a dispensing pharmacist to meet the requirements of pharmacy practice for dispensing prescription drugs to LTC residents, including but not limited to the performance of drug utilization review (DUR). In addition, the NLTCP pharmacist must conduct DUR to routinely screen for allergies and drug interactions, to identify potential adverse drug reactions, to identify inappropriate drug usage in the LTC population, and to promote cost effective therapy in the LTC setting. The NLTCP must also be equipped with pharmacy software and systems sufficient to meet the needs of prescription drug ordering and distribution to an LTC facility. Further, the NLTCP must provide written copies of the NLTCP's pharmacy procedures manual and said manual must be available at each LTC facility nurses' unit. NLTCPs are also required to provide ongoing in-service training to assure that LTC facility staff are proficient in the NLTCP's processes for ordering and receiving of medications. NLTCP must be responsible for return and/or disposal of unused medications following discontinuance, transfer, discharge, or death as permitted by State Boards of Pharmacy. Controlled substances and out of date substances must be disposed of within State and Federal guidelines.	
3.	Special Packaging NLTCPs must have the capacity to provide specific drugs in Unit of Use Packaging, Bingo Cards, Cassettes, Unit Dose or other special packaging commonly required by LTC facilities. NLTCPs must have access to, or arrangements with, a vendor to furnish supplies and equipment including but not limited to labels, auxiliary labels, and packing machines for furnishing drugs in such special packaging required by the LTC setting.	

4. IV Medications NLTCPs must have the capacity to provide IV medications t the LTC resident as ordered by a qualified medical professional. NLTCPs mu have access to specialized facilities for the preparation of IV prescriptions (cle room). Additionally, NLTCPs must have access to or arrangements with a vendor to furnish special equipment and supplies as well as IV trained pharmacists and technicians as required to safely provide IV medications.	Ist
5. Compounding /Alternative Forms of Drug Composition NLTCPs must be capable of providing specialized drug delivery formulations as required for sor LTC residents. Specifically, residents unable to swallow or ingest medications through normal routes may require tablets split or crushed or provided in suspensions or gel forms, to facilitate effective drug delivery.	
 Pharmacist On-call Service NLTCP must provide on-call, 24 hours a day, 7 days a week service with a qualified pharmacist available for handling calls af hours and to provide medication dispensing available for emergencies, holida and after hours of normal operations. 	ter
7. Delivery Service NLTCP must provide for delivery of medications to the LTC facility up to seven days each week (up to three times per day) and in-betwee regularly scheduled visits. Emergency delivery service must be available 24 hours a day, 7 days a week. Specific delivery arrangements will be determine through an agreement between the NLTCP and the LTC facility. NLTCPs mu provide safe and secure exchange systems for delivery of medication to the L facility. In addition, NLTCP must provide medication cassettes, or other stand delivery systems, that may be exchanged on a routine basis for automatic restocking. The NLTCP delivery of medication to carts is a part of routine "dispensing".	n ed ist TC
8. Emergency Boxes NLTCPs must provide "emergency" supply of medication as required by the facility in compliance with State requirements.	IS
 Emergency Log Books NLTCP must provide a system for logging and charge medication used from emergency/first dose stock. Further, the pharmacy must maintain a comprehensive record of a resident's medication order and drug administration. 	
10. Miscellaneous Reports, Forms and Prescription Ordering Supplies NLTCP must provide reports, forms and prescription ordering supplies necessary for t delivery of quality pharmacy care in the LTC setting. Such reports, forms and prescription ordering supplies may include, but will not necessarily be limited provider order forms, monthly management reports to assist the LTC facility ir managing orders, medication administration records, treatment administration records, interim order forms for new prescription orders, and boxes/folders for order storage and reconciliation in the facility.	to, ו ו

HPMS Part D Contacts

A. In HPMS, on the Contract Management/Contact Information/Contact Data Page provide the name/title, mailing address, phone number, fax number, and email address for the following Applicant contacts. We recognize that due to the many PACE Part D waivers, several of the requested contacts bear no relevance for PACE organizations. However, for systems purposes all sections must be populated. Therefore, in instances where a contact does not apply, please list the Application Contact.

Contact	Name/Title	Mailing Address	Phone/Fax Numbers	Email Address
Corporate				
Mailing				
CEO – Sr.				
Official for				
Contracting				
Chief Financial				
Officer				
Medicare				
Compliance				
Officer				
Enrollment				
Contact				
Medicare				
Coordinator				
System Contact				
Customer				
Service				
Operations				
Contact				
General				
Contact				
User Access				
Contact				
Backup User				
Access Contact				
Marketing				
Contact				
Medical				
Director				
Bid Primary				
Contact				
Payment				
Contact				
Pharmacy				
Benefit				
Manager				
Contact				
Part D Claims				

Submission		
Contact		
Formulary		
Contact		
Pharmacy		
Network		
Management		
Contact		
Medication		
Therapy		
Management		
Contact		

Contact	Name/Title	Mailing Address	Phone/Fax Numbers	Email Address
Patient Safety		71001000	Turnboro	
Contact				
Part D Benefits				
Contact				
Part D Quality				
Assurance				
Contact				
Part D				
Application				
Contact				
Pharmacy				
Director				
HIPAA Security Officer				
HIPAA Privacy Officer				
Part D Price				
File Contact				
(Primary)				
Part D Price				
File Contact				
(Back-up)				
Part D Appeals				
Government				
Relations				
Contact				
Emergency				
Part D Contact				
Pharmacy				
Technical Help				
Desk Contact				

		1
Processor		
Contact		
CMS Casework		
Communication		
Contact		
Part D		
Exceptions		
Contact		
EOB Transfer		
Contact		
Coordination of		
Benefits		
Contact		
CEO – CMS		
Administrator		
Contact		
Plan to Plan		
Reconciliation		
Contact		
CAP Report		
Contact for		
Public Website		

B. Complete the table below:

APPLICANT MUST ATTEST 'YES' TO THE FOLLOWING			Requesting
QUALIFICATION TO BE APPROVED FOR A PART D	YES	NO	Waiver? –
CONTRACT. ATTEST 'YES' OR 'NO' TO THE FOLLOWING			Yes or No
QUALIFICATION BY PLACING A CHECKMARK IN THE			
RELEVANT COLUMN:			
1. Applicant agrees that CMS may release contact information to States, SPAPs, providers, Part D sponsors, and others who need the contact information for legitimate purposes.			

Business Integrity

APPLICANT MUST ATTEST 'YES' TO THE FOLLOWING QUALIFICATION TO BE APPROVED FOR A PART D CONTRACT. ATTEST 'YES' OR 'NO' TO THE FOLLOWING QUALIFICATION BY PLACING A CHECKMARK IN THE RELEVANT COLUMN:	Yes	No	Requesting Waiver? – Yes or No
 Applicant, applicant staff, and its affiliated companies, subsidiaries or subcontractors (first tier, downstream and 			

	related entities), and subcontractor (first tier, downstream and related entities) staff agree that they are bound by 2 CFR Part 376 and attest that they are not excluded by the Department of Health and Human Services Office of the Inspector General or by the General Services Administration. Please note that this includes any member of its board of directors, and any key		
	management or executive staff or any major stockholder.		
2.	Applicant has no past or pending investigations, legal actions, administrative actions, or matters subject to arbitration brought involving the Applicant (and Applicant's parent firm if applicable), including any key management or executive staff,		
	by a government agency (state or federal including CMS) over the past three years on matters relating to payments from governmental entities, both federal and state, for healthcare and/or prescription drug services.		
3.	Applicant's Pharmaceutical Benefit Manager (PBM) (and the PBM's parent firm if applicable) has no past or pending investigations, legal actions, administrative actions, or matters subject to arbitration brought involving the PBM (and PBM's parent firm if applicable) including any key management or executive staff, by a government agency (state or federal including CMS) over the past three years on matters relating to payments from governmental entities, both federal and state, for healthcare and/or prescription drug services.		

B. If Applicant answered No to Attestation #2 and/or Attestation #3, provide as an attachment, all past or pending, if known, investigations, legal actions, administrative actions, or matters subject to arbitration brought by a government agency (state or federal including CMS over the past three years on matters relating to payments from governmental entities, for healthcare and/or prescription drug services involving the following:

- 1) Applicant (and Applicant's parent firm if applicable);
- 2) PBM (and PBM's parent firm if applicable);
- 3) Key management of executive staff.

Provide as part of the attachment a brief explanation of each action, including the following:

- 1) Legal names of the parties;
- 2) Circumstances;
- 3) Status (pending or closed);
- 4) If closed, provide the details concerning resolution and any monetary payments; and
- 5) Settlement agreements or corporate integrity agreements.

Compliance Plan

APPLICANT MUST ATTEST 'YES' T	O EACH OF THE			Requesting
FOLLOWING QUALIFICATIONS TO	BE APPROVED FOR A	YES	NO	Waiver? –
PART D CONTRACT. ATTEST 'YES'	OR 'NO' TO EACH OF			Yes or No
THE FOLLOWING QUALIFICATIONS	S BY PLACING A			
CHECKMARK IN THE RELEVANT C	OLUMN:			
 Applicant will implement a Part D of accordance with all Federal and St guidelines, including Chapter 9—P Fraud, Waste and Abuse of the Pr Manual by time of CMS contract w compliance plan must clearly estat D. 	tate regulations and Part D Program to Control escription Drug Benefit ith the Part D sponsor. The			
 Applicant will implement a Part D or consists of written policies, proced conduct addressing Part D issues organization's commitment to abid and State standards. 	ures, and standards of and articulating your			
 Applicant will implement a Part D or designates an employee as the co compliance committee accountable (Note: This requirement cannot be subcontractor (first tier, downstrea) 	mpliance officer and e to senior management. e delegated to a			
4. Applicant will implement a Part D of includes effective training and edu compliance officer and the Part D of managers and directors and the Part downstream and related entities. I aspects of the compliance plan are to remember that the Applicant's c maintain appropriate oversight of t	cation between the Applicant's employees, art D Applicant's first tier, Note: To the extent that e delegated, it is important compliance officer must			
 Applicant will implement a Part D of includes effective lines of commun compliance officer, members of the the Part D Applicant's employees, and the Part D Applicant's first tier entities. 	compliance plan that ication between the e compliance committee, managers and directors			
 Applicant will implement a Part D of includes disciplinary standards that the organization. 	· ·			
 Applicant will implement a Part D or includes procedures for internal more operations as they relate to Part D 	onitoring and auditing of			
 Applicant will implement a Part D of includes procedures for ensuring p 				

Part D offenses and development of corrective action initiatives, relating to the Applicant's contract as a Part D sponsor. This compliance should include procedures to		
voluntarily self report potential fraud or misconduct related to the Part D program to CMS or its designee.		
the Part D program to CMS of its designee.		

B. Provide as an attachment a copy of your organization's Medicare Part D Compliance Plan and/or compliance policies and procedures that you intend to use for this contract.

The Part D compliance plan and any related policies and procedures must clearly articulate that the appropriate elements listed at 42 CFR 423.504(b)(4)(vi) and in the Part D Program Integrity Manual are being implemented within the context of the compliance plan and are specific to the issues and challenges presented by the Part D program. A general compliance plan applicable to healthcare operations is not sufficient.

Note: Please be advised that the Part D Sponsor is ultimately responsible for the implementation and monitoring of the day-to-day operations of its Part D compliance program. As applicable, Section 40.1 of Chapter 9 of the Prescription Drug Benefit Manual indicates that the compliance officer and compliance committee functions may not be delegated or subcontracted. A compliance plan adopted and operated by a Part D Applicant's subcontractor (first tier, downstream and related entities) is not sufficient to demonstrate that the Part D Applicant meets the compliance program requirement.

Electronic Prescription Program

APPLICANT MUST ATTEST 'YES' TO THE FOLLOWING QUALIFICATION TO BE APPROVED FOR A PART D CONTRACT. ATTEST 'YES' OR 'NO' TO THE FOLLOWING QUALIFICATION BY PLACING A CHECKMARK IN THE RELEVANT COLUMN:	YES	NO	Requesting Waiver? Yes or No
 Applicant agrees to follow the current electronic prescribing rules. 			

Enrollment and Eligibility

APPLICANT MUST ATTEST 'YES' TO EACH OF THE			Requesting
FOLLOWING QUALIFICATIONS TO BE APPROVED FOR A	YES	NO	Waiver?
PART D CONTRACT. ATTEST 'YES' OR 'NO' TO EACH OF			Yes or No
THE FOLLOWING QUALIFICATIONS BY PLACING A			
CHECKMARK IN THE RELEVANT COLUMN:			
1. Applicant agrees to comply with operational guidance on Creditable Coverage and the Late Enrollment Penalty.			
 2. Applicant will query the Batch Eligibility Query (BEQ) or the User Interface (UI) to receive: a) Verification of Medicare Eligibility b) The end date of the beneficiary's Part D IEP; 			
 c) Periods of enrollment in a Medicare plan that provides prescription drug coverage, and; d) Periods of enrollment in a retiree prescription drug plan whose sponsor receives a retiree subsidy from Medicare. 			
3. Applicant will collect, review and transmit creditable coverage information in accordance with CMS guidance and policies.			
4. Applicant agrees to use the information provided by CMS, including the Low-Income Subsidy/Part D Premium Report Data File to determine match rates of their information to that of CMS.			
5. Applicant agrees not to disenroll members for failure to pay premiums (or notify them of impending disenrollment) in cases where the member has requested that premiums be withheld from his/her Social Security benefit check until the organization receives a reply from CMS indicating that the member's request has been rejected.			
 Applicant agrees that it may not disenroll a member or initiate the disenrollment process if the organization has been notified that a State Pharmaceutical Assistance Program (SPAP) or other payer intends to pay the entire Part D premium on behalf of an individual. 			

Complaints Tracking

AF	PLICANT MUST ATTEST 'YES' TO EACH OF THE			Requesting
FOLLOWING QUALIFICATIONS TO BE APPROVED FOR A		YES	NO	Waiver?
PART D CONTRACT. ATTEST 'YES' OR 'NO' TO EACH OF				Yes or No
THE FOLLOWING QUALIFICATIONS BY PLACING A				
CHECKMARK IN THE RELEVANT COLUMN:				
1.	Applicant will resolve immediate needs complaints via the CMS Complaints Tracking Module (CTM) within 2 business days.			
2.	Applicant will continue to monitor and document complaint resolutions for complaints attributed to their contracts in the CMS' CTM in accordance with CMS' Standard Operating Procedures for Part D sponsors.			
3.	Applicant will maintain Standard Operating Procedures that address how your organization will handle and quickly resolve immediate action cases.			

Coordination of Benefits

APPLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING QUALIFICATIONS TO BE APPROVED FOR A PART D CONTRACT. ATTEST 'YES' OR 'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING A CHECKMARK IN THE RELEVANT COLUMN:	YES	NO	Requesting Waiver? Yes or No
 Applicant agrees to comply with Coordination of Benefits guidance. 			
 Applicant develops and operates a system for collecting information from enrollees about enrollees' other health insurance, including whether such insurance covers outpatient prescription drugs. 			
 Applicant will permit SPAPs and other third party payers to coordinate benefits as required by the regulations in 42 CFR Part 423.464(a)(b)(d)(e). For example, an SPAP might pay the premium for supplemental benefits on behalf of a beneficiary, or pay a beneficiary's cost-sharing. 			
4. Applicant agrees not to impose fees on SPAPs or other third- party insurers unrelated to the cost of coordination of benefits.			

Tracking Out-of-Pocket Costs (TrOOP)

A. Complete the table below:

APPLICANT MUST ATTEST 'YES' TO EACH OF THE			Requesting
FOLLOWING QUALIFICATIONS TO BE APPROVED FOR A		NO	Waiver?
PART D CONTRACT. ATTEST 'YES' OR 'NO' TO EACH OF			Yes or No
THE FOLLOWING QUALIFICATIONS BY PLACING A			
CHECKMARK IN THE RELEVANT COLUMN:			
 Applicant will track each enrollee's true out of pocket (TrOOP) costs reflecting the amount the enrollee has spent out of pocket during a program year on covered Part D drugs. 			
 Applicant will accept data concerning third party payers in a format specified by CMS for use in the Applicant's TrOOP calculation. 			
3. In the event of disenrollment, Applicant agrees to provide the beneficiary's TrOOP data (i.e., gross covered drug spending and TrOOP balances from any prior Part D plans in which the beneficiary was enrolled during the coverage year) as of the effective date of the disenrollment.			
4. Applicant agrees to receive and respond promptly to transactions requesting TrOOP-related data (i.e., gross covered drug spending and TrOOP balances from any prior Part D plans in which the beneficiary was enrolled during the coverage year) for disenrolling Part D beneficiaries as well as to receive these data for newly enrolling Part D beneficiaries transferring mid-year from another plan.			

• NOTE: For information regarding the TrOOP facilitator, Applicant may link to http://medifacd.ndchealth.com/

Medicare Secondary Payer

APPLICANT MUST ATTEST 'YES' TO EACH OF THE			Requesting
FOLLOWING QUALIFICATIONS TO BE APPROVED FOR A	YES	NO	Waiver?
PART D CONTRACT. ATTEST 'YES' OR 'NO' TO EACH OF			Yes or No
THE FOLLOWING QUALIFICATIONS BY PLACING A			
CHECKMARK IN THE RELEVANT COLUMN:			
1. Applicant is familiar with rules that determine when other payers are primary or secondary to Medicare as referenced in 42 CFR 423.180(d)			
2. Applicant will adhere to MSP laws and any other Federal and State laws in establishing payers of last resort.			
3. Applicant will follow the Rules for Coordination of Benefits adopted in the most current National Association of Insurance Commissioner Coordination of Benefits Model Regulation as applicable.			
4. Applicant will collect mistaken primary payment from insurers, group health plans, employer sponsors, enrollees and other entities.			
5. Applicant agrees that in situations involving workers' compensation claims, the Applicant makes an effort to determine which Part D drugs will be included as part of workers' compensation future medical payments (i.e., those services and items provided after the final settlement) and ensures that it does not make (or recover) payment for such drugs.			

Data Collection and Reporting Requirements

APPLICANT MUST ATTEST 'YES'	TO EACH OF THE			Requesting
FOLLOWING QUALIFICATIONS TO	D BE APPROVED FOR A	YES	NO	Waiver?
PART D CONTRACT. ATTEST 'YE	S' OR 'NO' TO EACH OF			Yes or No
THE FOLLOWING QUALIFICATION	NS BY PLACING A			
CHECKMARK IN THE RELEVANT	COLUMN:			
REBATE DATA				
 The Applicant or the Applicant's accounting systems capable of a documentation, as specified by 0 and completeness of rebate data provided to CMS in response to 	Complishing the provision of CMS, to support the accuracy . Documentation will be			
 The Applicant will report rebate of the manufacturer/brand name lev package size not required) in the 	lollars on a quarterly basis at /el (unique strength and			
 The Applicant or the Applicant's accounting systems capable of a of financial reports to support ret accounting must allow for step-d rebates received at the aggregat down to the level of plan enrollee 	complishing the production bate accounting. The rebate own cost reporting in which e level may be apportioned			

Data Exchange Between PACE Organizations and CMS

APPLICANT MUST ATTEST 'YES' TO EACH OF THE			Requesti
FOLLOWING QUALIFICATIONS TO BE APPROVED FOR A	YES	NO	ng
PART D CONTRACT. ATTEST 'YES' OR 'NO' TO EACH OF			Waiver?
THE FOLLOWING QUALIFICATIONS BY PLACING A			Yes or No
CHECKMARK IN THE RELEVANT COLUMN:			
HPMS			
 Applicant will use HPMS to communicate with CMS in support of the Part D application process, formulary submission process, bid submission process, ongoing operations of the Part D program, and reporting and oversight activities. PACE Organizations are required to secure access to HPMS in order to carry out these functions. 			
ENROLLMENT & PAYMENT			
 Applicant will establish connectivity to CMS noted in the instructions provided by the MMA Help Desk at 1-800-927- 8069 or via the MMA HelpDesk webpage, <u>www.cms.hhs.gov/mmahelp</u>, in the Plan Reference Guide for CMS Part C/D system link. 			
3. Applicant will obtain CMS User ID and Password.			
4. Applicant will submit enrollment, disenrollment and change transactions to communicate membership information to CMS each month.			
5. Applicant will reconcile Part D data to CMS enrollment/payment reports within 45 days of availability.			
 Applicant will submit enrollment/payment attestation forms within 45 days of CMS report availability. 			
7. Applicant will participate in connectivity testing and other system testing measures as provided to the Applicants prior to contract execution to validate system setup.			
8. Applicant will establish system(s) to process enrollment and payment transactions as exchanged with CMS in accordance with system development lifecycle standards.			
9. Applicant will ensure appropriate security safeguards and protocols are in place to protect the protected health information in the system(s).			
10. Applicant will maintain all pertinent system security and disaster recovery plans and procedures.			

Health Insurance Portability and Accountability Act of 1996 (HIPAA)

APPLICANT MUST ATTEST 'YES' TO EACH OF THE			Requesting
FOLLOWING QUALIFICATIONS TO BE APPROVED	YES	NO	Waiver?
FOR A PART D CONTRACT. ATTEST 'YES' OR 'NO'			Yes or No
TO EACH OF THE FOLLOWING QUALIFICATIONS BY			
PLACING A CHECKMARK IN THE RELEVANT			
COLUMN:			
1. Applicant will comply with any applicable standards, implementation specifications, and requirements in the Standards for Privacy of Individually Identifiable Health Information under 45 CFR Parts 160 and 164 subparts A and E.			
2. Applicant will comply with any applicable standards, implementation specifications, and requirements in the Security Standards under 45 CFR Parts 160, 162 and 164			
 Applicant agrees to encrypt all hard drives or other storage media within the device as well as all removable media. 			
4. Applicant agrees to develop and implement a policy addressing the handling of portable media that is accessed or used outside of the organization's physical purview.			
5. Applicant will comply with any applicable standards, implementation specifications, and requirements in the Standard Unique Health Identifier for Health Care Providers under 45 CFR Part 160 and 162.			
6. Applicant agrees that when its organization received a National Provider Identifier (NPI) in prescription drug event data, that the organization must report an NPI.			
7. Applicant agrees that when its organization received a National Provider Identifier (NPI) it will implement a contingency plan related to compliance with the NPI provisions.			
8. Applicant will comply with any applicable standards, implementation specifications, and requirements in the Standards for Electronic Transactions under 45 CFR Parts 160 and 162 subparts I <i>et seq</i> .			
9. Applicant agrees to submit the Offshore Subcontract Information and Attestation for each offshore subcontractor (including downstream offshore subcontractors (first tier, downstream and related entities) that receive, process, transfer, handle, store, or access Medicare beneficiary protected health information (PHI) by the last Friday in September of the upcoming contract year.			

Prohibition on Use of SSN or Medicare ID number on Enrollee ID Cards

APPLICANT MUST ATTEST 'YES' TO EACH OF THE			Requesting
FOLLOWING QUALIFICATIONS TO BE APPROVED FOR A	YES	NO	Waiver?
PART D CONTRACT. ATTEST 'YES' OR 'NO' TO EACH OF			Yes or No
THE FOLLOWING QUALIFICATIONS BY PLACING A			
CHECKMARK IN THE RELEVANT COLUMN:			
 Applicant agrees not to use an enrollee's Social Security Number (SSN) or Medicare ID Number on the enrollee's identification card. 			

Claims Processing

APPLICANT MUST ATTEST 'YES' TO EACH OF THE			Requesting
FOLLOWING QUALIFICATIONS TO BE APPROVED FOR A PART	YES	NO	Waiver?
D CONTRACT. ATTEST 'YES' OR 'NO' TO EACH OF THE		NO	Yes or No
FOLLOWING QUALIFICATIONS BY PLACING A CHECKMARK IN			
THE RELEVANT COLUMN:			
 Applicant will either: (a) Contract with a third party that agrees to develop and operate an on-line claims processing system that operates in real time to ensure accurate and timely payment of all claims submitted by network pharmacies. System operates according to the following standards:			
claims submitted by network pharmacies.			
 2. Applicant will develop and operate a paper claims processing system designed to pay claims submitted by non-network pharmacies on behalf of Part D plan enrollees. Applicant processes claims according to the following standards: 100% of claims requiring no intervention handled within 15 calendar days; 100% of claims requiring intervention handled within 30 calendar days; 99% of all manually keyed claims paid with no errors. Note: This is in contrast to paper claims submitted by beneficiaries per the regulations at 42 CFR §423.568(b). 			
 3. Applicant will develop and have available for CMS inspection a complete description of your claims adjudication system including: Hardware and software; Operating system; MediSpan or First Data Bank database, including number of iterations saved; 			

 Number of sites processing claims (including disaster recovery back-up system); System volume in covered lives, including the number of transactions the system can support per day and per hour. 		
 4. Applicant will develop and have available to CMS upon request policies and procedures that include a complete description and flow chart detailing the claims adjudication process for each: Contracted network pharmacies; Out-of-network pharmacies; Paper claims; Batch-processed claims; Manual claim entry (e.g. for processing direct member reimbursement) 		
 5. Applicant will develop and will make available to CMS upon request policies and procedures that include a complete description of claim detail management, including: The length of time that detailed claim information is maintained online (not less than 12 months); The data storage process after it is no longer online; The length of time that detailed claim information is stored when it is no longer online (not less than 10 years). 		

 6. Applicant will develop and have available to CMS upon request policies and procedures that include a complete description of the accessibility of this information for data capture purposes and flow chart of the claims data retrieval process for each: Entire claims history file; Encounter data required by state mandates; Encounter data required by alternate funding sources; Out-of-pocket maximum/deductible files (not applicable to Medicare-only plan members). 		
7. Applicant will develop and have available to CMS upon request policies and procedures that include a description of how overpayments and underpayments to pharmacies, and/or enrollees (including other payers who have paid on behalf of the enrollee) are processed, including recovery procedures.		
 8. In accordance with sections 460.122 and 460.124 of the PACE regulation, applicant will develop and have available to CMS upon request policies and procedures that include a complete description of procedures surrounding disputed claims, including: The steps that a pharmacy and/or enrollee must follow to dispute a claim reimbursement; The average amount of time needed to resolve a claims dispute; Turnaround time standards for dispute resolution. 		
9. Applicant will have a robust testing process that will identify and correct any plan configuration errors prior to implementation.		
10. Applicant will accept from eligibility files and any prior claims data electronically in NCPDP format.		
11. Applicant will document the manner and extent to which it has tested benefit designs such as drugs excluded or quantity limitations and plan parameters such as the dual eligible plan vs. the Medicare-only plan.		
12. Applicant agrees to rapidly adopt any new messaging approved by the NCPDP Workgroup to adjudicate a Part D claim and appropriately coordinate benefits in real time.		

Record Retention

APPLICANT MUST ATTEST 'YES' TO EACH OF THE FOLLOWING			Request
QUALIFICATIONS TO BE APPROVED FOR A PART D CONTRACT.	YE	NO	ing
ATTEST 'YES' OR 'NO' TO EACH OF THE FOLLOWING	S		Waiver?
QUALIFICATIONS BY PLACING A CHECKMARK IN THE RELEVANT			Yes or
COLUMN:			No
 The Applicant will maintain, for 10 years, books, records, documents, and other evidence of accounting procedures and practices consisten with 42 CFR §423.505(d). 			
2. Applicant agrees to have pharmacies, contracted for the Part D benefit, maintain prescription records in their original format for the greater of 3 years or the period required by State law and allow those records to be transferred to an electronic format that replicated the original prescription for the remaining 7 years of the 10 year record retention requirement.			
 Applicant agrees to keep all other records—except prescription records—that must be retained for Medicare under Part D and Part D in the format(s) required by either State law or the HIPAA Privacy Rule, if applicable, or at the Applicant's discretion. 			

CERTIFICATION

I, the undersigned, certify to the following:

- I have read the contents of the completed application and the information contained herein is true, correct, and complete. If I become aware that any information in this application is not true, correct, or complete, I agree to notify the Centers for Medicare & Medicaid Services (CMS) immediately and in writing.
- 2) I authorize CMS to verify the information contained herein. I agree to notify CMS in writing of any changes that may jeopardize my ability to meet the qualifications stated in this application prior to such change or within 30 days of the effective date of such change. I understand that such a change may result in termination of the approval.
- 3) I agree that if my organization meets the minimum qualifications and is Medicareapproved, and my organization enters into a Part D Addendum with CMS, I will abide by the requirements contained in this Application and provide all required services outlined in this application and in accordance with sections 1894 and 1934 of the Act.
- 4) I agree that CMS may inspect any and all information necessary including inspecting of the premises of the Applicant's organization or plan to ensure compliance with stated Federal requirements including specific provisions for which I have attested. I further agree to immediately notify CMS if despite these attestations I become aware of circumstances which preclude full compliance by January 1, 2010 with the requirements stated here in this application as well as in Part 423 of 42 CFR of the regulation.
- 5) I understand that in accordance with 18 U.S.C. § 1001, any omission, misrepresentation or falsification of any information contained in this application or contained in any communication supplying information to CMS to complete or clarify this application may be punishable by criminal, civil, or other administrative actions including revocation of approval, fines, and/or imprisonment under Federal law.
- 6) I further certify that I am an authorized representative, officer, chief executive officer, or general partner of the business organization that is applying for qualification to enter into a Part D Addendum with CMS.
- 7) For several of the Part D program requirements described in this solicitation, CMS has issued operational policy guidance that provides more detailed instructions to Part D sponsors. Organizations submitting an application in response to this solicitation acknowledge that they are also representing to CMS that they have reviewed the associated guidance materials posted on the CMS web site and will comply with such guidance should they be approved for a Part D contract. Applicants must visit the CMS web site periodically to stay informed about new or revised guidance documents.

Authorized Representative Name (printed)

Title

Authorized Representative Signature

Date (MM/DD/YYYY)

Applicability of Formulary Submission Requirements

APPLICABILITY OF FORMULARY SUBMISSION REQUIREMENT

For purposes of formulary submission and review, the following paragraphs describe the definition of a formulary.

1. COST SHARING TIERS

Any coverage list that utilizes more than one cost sharing tier with differential co-pay or coinsurance, is considered a formulary.

2. PRIOR AUTHORIZATION

Any coverage list that contains one or more drugs that must undergo prior authorization before dispensing is considered a formulary. If in the normal course of clinical practice, the prescribing physician uses FDA-approved indications and use criteria to determine appropriateness of therapy, this is not considered prior authorization.

3. STEP THERAPY

Any coverage list that contains one or more drugs that are part of a step therapy management program is considered a formulary. This includes any program that requires a certain drug to be used first, before a different drug can be dispensed. Step therapy can apply to certain drug classes or among brand and generic drug combinations.

4. QUANTITY LIMITATIONS

Any coverage list that contains one or more drugs with quantity limits is considered a formulary. Quantity limits are often used in cases where FDA-approved prescribing instructions state that only a certain number of doses should be used in a certain time period.

5. STEERAGE

Any coverage list that contains one or more drugs that are considered preferred or drugs that are steered towards is considered a formulary. Common prescribing patterns are not considered steerage as long as there are no adverse consequences to physicians or patients if a particular drug is not chosen.

If a plan meets any of the five criteria referenced above, then their coverage list is considered a formulary and needs to be submitted to CMS for review and approval.

Only those applicants that answer yes to 1 or more of items 1-5 listed above will be required to adhere to formulary requirements specified in section 423.120(b) and complete the forms that follow.

Formulary/Pharmacy and Therapeutics (P&T) Committee

A. Complete the form below:

APPLICANT MUST ATTEST 'YES' OR 'NO' TO THE FOLLOWING		
QUALIFICATION TO BE APPROVED FOR A PART D CONTRACT. ATTEST	YES	NO
YES' OR 'NO' TO EACH OF THE FOLLOWING QUALIFICATIONS BY PLACING		
A CHECKMARK IN THE RELEVANT COLUMN IN HPMS.		
1. Applicant will submit a formulary to CMS for the Part D benefit.		
 Applicant agrees to comply with formulary guidance that is contained in Chapter 6 of the Prescription Drug Benefit Manual. 		
3. Applicant agrees, where using a formulary, to meet all formulary submission deadlines established by CMS. Applicant further agrees that CMS may discontinue its review of the Applicant's formulary submission upon the Applicant's failure to meet any of the formulary submission deadlines. Applicant acknowledges that failure to receive CMS approval of its formulary may prevent CMS from approving the Applicant's bid(s) and contracting with the Applicant for the following benefit year.		
4. Applicant agrees that its formulary must include substantially all drugs in the six categories of clinical concern that are available on the CMS-established formulary upload date. Applicant further agrees that any new drugs or newly approved uses for drugs within the six classes that come onto the market after the CMS-established formulary upload date will be subject to an expedited Pharmacy and Therapeutic committee review. The expedited review process requires P&T committees to make a decision within 90 days, rather than the normal 180-day requirement.		
5. Applicant will provide for an appropriate transition for new enrollees prescribed Part D drugs that are not on its formulary. This transition process must satisfy the requirements specified in Chapter 6 of the Prescription Drug Benefit Manual.		
6. Applicant agrees to submit to CMS a description of the organization's approach to transitioning beneficiaries on drug regimens that are not on the plan's Part D approved formulary by close of business on the CMS-established formulary upload date through HPMS.		
7. Applicant agrees, where appropriate, to extend transition periods beyond 30 days for enrollees using non-formulary drugs that have not been transitioned to a formulary drug or gone through the plan exception process within 30 days.		
8. Applicant agrees to ensure that staffs are trained on and information systems are in place to accommodate administration of the transition policy. This includes adoption of necessary information system overrides.		
9. Applicant will establish an emergency supply of non-formulary Part D drugs (31- day supplies, unless the prescription if written for fewer days) for long-term care residents to allow the plan and/or the enrollee time for the completion of an exception request to maintain coverage of an existing drug based on reasons of		

medical necessity.	
10. Applicant will establish appropriate timeframes and "first fill" procedures to non- formulary Part D medications in long-term care and retail settings.	
11. Applicant will abide by CMS guidance related to vaccine administration reimbursement under Part D.	

B. Complete the form below:

INCLUDE THE USE OF A FORMULARY, THEN APPLICANT MUST YES NO Waiver? ALSO PROVIDE A P&T COMMITTEE MEMBER LIST EITHER Yes or No DIRECTLY OR THROUGH ITS PHARMACY BENEFIT MANAGER Yes or No (PBM). APPLICANT MUST ATTEST 'YES' OR 'NO' THAT IT IS USING ITS PBM'S P&T COMMITTEE, TO BE APPROVED FOR A PART D CONTRACT. ATTEST 'YES' OR 'NO' BY PLACING A CHECKMARK IN THE RELEVANT COLUMN IN HPMS. 1. Applicant is using the P&T Committee of its PBM for purposes of the Pat D benefit. 2. 2. If answered yes to B1_Applicant's PBM is operating under a confidentiality agreement for purposes of the P&T Committee (meaning Applicant has no knowledge of the membership of the PBM'S P&T. Committee). (If not applicable, check "NO.") Note: If answer is YES, then Applicant must complete the P&T Committee Certification Statement and PBM must complete the D&T Committee P&T Committee Member List and Certification Statement, 3. Applicant will develop and use a P&T committee to develop and review the formulary and to ensure that the formulary is appropriately revised to adapt to both the number and types of drugs on the market. Note: While the P&T committee may be involved in providing recommendations regarding the placement of a particular Part D drug on a formulary cost-sharing tier, the ultimate decision maker on such formulary design issues is the Part D plan, and that decision maker on such formulary design issues is the Part D plan, and that decision maker on the ormically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review	IF APPLICANT IS INTENDING FOR ITS PART D BENEFIT TO			Requesting
DIRECTLY OR THROUGH ITS PHARMACY BENEFIT MANAGER (PBM). APPLICANT MUST ATTEST 'YES' OR 'NO' THAT IT IS USING ITS PBM'S P&T COMMITTEE, TO BE APPROVED FOR A PART D CONTRACT. ATTEST 'YES' OR 'NO' BY PLACING A CHECKMARK IN THE RELEVANT COLUMN IN HPMS. 1. Applicant is using the P&T Committee of its PBM for purposes of the Part D benefit. 2. If answered yes to B1, Applicant's PBM is operating under a confidentiality agreement for purposes of the P&T Committee (meaning Applicant has no knowledge of the membership of the PBM's P&T Committee). (If not applicable, check "NO.") Note: If answer is YES, then Applicant must complete the P&T Committee Member List located in the Appendix entitled Applicant Submission of P&T Committee Member List and Certification Statement. 3. Applicant will develop and use a P&T committee to develop and review the formulary and to ensure that the formulary is appropriately revised to adapt to both the number and types of drugs on the market. Note: While the P&T committee may be involved in providing recommendations regarding the placement of a particular Part D drug on a formulary cost-sharing tier, the ultimate decision maker on such formulary cost-sharing tier, the ultimate decision maker on such formulary design issues is the Part D plan, and that decision weighs both clinical and non-clinical factors. 4. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. Applicant will assure that the P&T	INCLUDE THE USE OF A FORMULARY, THEN APPLICANT MUST	YES	NO	Waiver?
(PBM). APPLICANT MUST ATTEST 'YES' OR 'NO' THAT IT IS USING ITS PBM'S P&T COMMITTEE, TO BE APPROVED FOR A PART D CONTRACT. ATTEST 'YES' OR 'NO' BY PLACING A CHECKMARK IN THE RELEVANT COLUMN IN HPMS. 1. Applicant is using the P&T Committee of its PBM for purposes of the Part D benefit. 2. If answered yes to B1, Applicant's PBM is operating under a confidentiality agreement for purposes of the P&T Committee (meaning Applicant has no knowledge of the membership of the PBM's P&T Committee). (If not applicable, check "NO.") Note: If answer is YES, then Applicant must complete the P&T Committee Certification Statement and PBM must complete the P&T Committee Member List located in the Appendix entitled Applicant Submission of P&T Committee Member List and Certification Statement. 3. Applicant will develop and use a P&T committee to develop and review the formulary and to ensure that the formulary is appropriately revised to adapt to both the number and types of drugs on the market. Note: While the P&T committee may be involved in providing recommendations regarding the placement of a particular Part D drug on a formulary cost-sharing tier, the ultimate decision maker on such formulary cost-sharing tier, the PAT D plan, and that decision weighs both clinical and non-clinical factors. 4. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. Applicant will assure that the P&T committee uses appropriate scientific and economic considerations to consider utili	ALSO PROVIDE A P&T COMMITTEE MEMBER LIST EITHER			Yes or No
(PBM). APPLICANT MUST ATTEST 'YES' OR 'NO' THAT IT IS USING ITS PBM'S P&T COMMITTEE, TO BE APPROVED FOR A PART D CONTRACT. ATTEST 'YES' OR 'NO' BY PLACING A CHECKMARK IN THE RELEVANT COLUMN IN HPMS. 1. Applicant is using the P&T Committee of its PBM for purposes of the Part D benefit. 2. If answered yes to B1, Applicant's PBM is operating under a confidentiality agreement for purposes of the P&T Committee (meaning Applicant has no knowledge of the membership of the PBM's P&T Committee). (If not applicable, check "NO.") Note: If answer is YES, then Applicant must complete the P&T Committee Member List located in the Appendix entitled Applicant Submission of P&T Committee Member List and Certification Statement. 3. Applicant will develop and use a P&T committee to develop and review the formulary and to ensure that the formulary is appropriately revised to adapt to both the number and types of drugs on the market. Note: While the P&T committee may be involved in providing recommendations regarding the placement of a particular Part D drug on a formulary cost-sharing tier, the ultimate decision maker on such formulary cost-sharing tier, the D plan, and that decision weighs both clinical and non-clinical factors. 4. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. Applicant will assure that the P&T committee uses appropriate scientific and economic considerations to consider utilization management activities that affect access to drugs, such as ac	DIRECTLY OR THROUGH ITS PHARMACY BENEFIT MANAGER			
USING ITS PBM'S P&T COMMITTEE, TO BE APPROVED FOR A PART D CONTRACT. ATTEST 'YES' OR 'NO' BY PLACING A CHECKMARK IN THE RELEVANT COLUMN IN HPMS. 1. Applicant is using the P&T Committee of its PBM for purposes of the Part D benefit. 2. If answered yes to B1_Applicant's PBM is operating under a confidentiality agreement for purposes of the P&T Committee (meaning Applicant has no knowledge of the membership of the PBM'S P&T Committee). (If not applicable, check "NO."). Note: If answer is YES, then Applicant must complete P&T Committee (Certification Statement and PBM must complete the P&T Committee (Certification Statement and PBM must complete the P&T Committee (Member List located in the Appendix entitled Applicant Submission of P&T Committee Member List and Certification Statement. 3. Applicant will develop and use a P&T committee to develop and review the formulary and to ensure that the formulary is appropriately revised to adapt to both the number and types of drugs on the market. Note: While the P&T committee may be involved in providing recommendations regarding the placement of a particular Part D drug on a formulary cost-sharing tier, the ultimate decision maker on such formulary design issues is the Part D plan, and that decision weighs both clinical and non-clinical factors. 4. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. Applicant's P&T committee view sets to consider utilization management activities that affect access to drugs, such as access to non-formulary d				
PART D CONTRACT. ATTEST 'YES' OR 'NO' BY PLACING A CHECKMARK IN THE RELEVANT COLUMN IN HPMS. 1. Applicant is using the P&T Committee of its PBM for purposes of the Part D benefit. 2. If answered yes to B1, Applicant's PBM is operating under a confidentiality agreement for purposes of the P&T Committee (meaning Applicant has no knowledge of the membership of the PBM's P&T Committee). (If not applicable, check "NO."). Note: If answer is YES, then Applicant must complete the P&T Committee (Member List located in the Appendix entitled Applicant Submission of P&T Committee Member List and Certification Statement. 3. Applicant will develop and use a P&T committee to develop and review the formulary and to ensure that the formulary is appropriately revised to adapt to both the number and types of drugs on the market. Note: While the P&T committee may be involved in providing recommendations regarding the placement of a particular Part D drug on a formulary cost-sharing tier, the ultimate decision maker on such formulary design issues is the Part D plan, and that decision weighs both clinical and non-clinical factors. 4. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. Applicant will assure that the P&T committee uses appropriate scientific and economic considerations to consider utilization management activities that affect access to drugs, such as access to non-formulary drugs, prior authorization, step therapy,				
CHECKMARK IN THE RELEVANT COLUMN IN HPMS. 1. Applicant is using the P&T Committee of its PBM for purposes of the Part D benefit. 2. If answered yes to B1_Applicant's PBM is operating under a confidentiality agreement for purposes of the P&T Committee (meaning Applicant has no knowledge of the membership of the PBM's P&T Committee). (If not applicable, check "NO.") Note: If answer is YES, then Applicant must complete P&T Committee Certification Statement and PBM must complete the P&T Committee (Member List located in the Appendix entitled Applicant Submission of P&T Committee Member List and Certification Statement. 3. Applicant will develop and use a P&T committee to develop and review the formulary and to ensure that the formulary is appropriately revised to adapt to both the number and types of drugs on the market. Note: While the P&T committee may be involved in providing recommendations regarding the placement of a particular Part D drug on a formulary cost-sharing tier, the ultimate decision maker on such formulary design issues is the Part D plan, and that decision weighs both clinical and non-clinical factors. 4. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. Applicant will assure that the P&T committee uses appropriate as access to non-formulary drugs, prior authorization, step therapy,	·			
1. Applicant is using the P&T Committee of its PBM for purposes of the Part D benefit. 2. If answered yes to B1_Applicant's PBM is operating under a confidentiality agreement for purposes of the P&T Committee (meaning Applicant has no knowledge of the membership of the PBM's P&T Committee). (If not applicable, check "NO.") Note: If answer is YES, then Applicant must complete P&T Committee Certification Statement and PBM must complete the P&T Committee Member List located in the Appendix entitled Applicant Submission of P&T Committee Member List and Certification Statement. 3. Applicant will develop and use a P&T committee to develop and review the formulary and to ensure that the formulary is appropriately revised to adapt to both the number and types of drugs on the market. Note: While the P&T committee may be involved in providing recommendations regarding the placement of a particular Part D drug on a formulary cost-sharing tier, the ultimate decision maker on such formulary cost-sharing tier, the ultimate decision maker on such formulary design issues is the Part D plan, and that decision weighs both clinical and non-clinical factors. 4. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. Applicant's that affect access to drugs, such as access to non-formulary drugs, prior authorization, step therapy,				
the Part D benefit. 2. If answered yes to B1_Applicant's PBM is operating under a confidentiality agreement for purposes of the P&T Committee (meaning Applicant has no knowledge of the membership of the PBM's P&T Committee). (If not applicable, check "NO.") Note: If answer is YES, then Applicant must complete P&T Committee Certification Statement and PBM must complete the P&T Committee (Member List located in the Appendix entitled Applicant Submission of P&T Committee Member List and Certification Statement. 3. Applicant will develop and use a P&T committee to develop and review the formulary and to ensure that the formulary is appropriately revised to adapt to both the number and types of drugs on the market. Note: While the P&T committee may be involved in providing recommendations regarding the placement of a particular Part D drug on a formulary cost-sharing tier, the ultimate decision maker on such formulary design issues is the Part D plan, and that decision weighs both clinical and non-clinical factors. 4. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. Applicant will assure that the P&T committee uses appropriate scientific and economic consider utilization management activities that affect access to drugs, such as access to non-formulary drugs, prior authorization, step therapy,	CHECKMARK IN THE RELEVANT COLUMN IN HPMS.			
confidentiality agreement for purposes of the P&T Committee (meaning Applicant has no knowledge of the membership of the PBM's P&T Committee). (If not applicable, check "NO.") Note: If answer is YES, then Applicant must complete P&T Committee Certification Statement and PBM must complete the P&T Committee Member List located in the Appendix entitled Applicant Submission of P&T Committee Member List and Certification Statement. 3. Applicant will develop and use a P&T committee to develop and review the formulary and to ensure that the formulary is appropriately revised to adapt to both the number and types of drugs on the market. Note: While the P&T committee may be involved in providing recommendations regarding the placement of a particular Part D drug on a formulary cost-sharing tier, the ultimate decision maker on such formulary design issues is the Part D plan, and that decision weighs both clinical and non-clinical factors. 4. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. Applicant will assure that the P&T committee uses appropriate scientific and economic considerations to consider utilization management activities that affect access to drugs, such as access to non-formulary drugs, prior authorization, step therapy,				
(meaning Applicant has no knowledge of the membership of the PBM's P&T Committee). (If not applicable, check "NO.") Note: If answer is YES, then Applicant must complete P&T Committee Certification Statement and PBM must complete the P&T Committee Member List located in the Appendix entitled Applicant Submission of P&T Committee Member List and Certification Statement. 3. Applicant will develop and use a P&T committee to develop and review the formulary and to ensure that the formulary is appropriately revised to adapt to both the number and types of drugs on the market. Note: While the P&T committee may be involved in providing recommendations regarding the placement of a particular Part D drug on a formulary cost-sharing tier, the ultimate decision maker on such formulary design issues is the Part D plan, and that decision weighs both clinical and non-clinical factors. 4. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. Applicant will assure that the P&T committee uses appropriate scientific and economic considerations to consider utilization management activities that affect access to drugs, such as access to non-formulary drugs, prior authorization, step therapy,				
PBM's P&T Committee). (If not applicable, check "NO.") Note: If answer is YES, then Applicant must complete P&T Committee Certification Statement and PBM must complete the P&T Committee Member List located in the Appendix entitled Applicant Submission of P&T Committee Member List and Certification Statement. 3. Applicant will develop and use a P&T committee to develop and review the formulary and to ensure that the formulary is appropriately review the formulary and to ensure that the formulary is appropriately review the formulary and to be involved in providing recommendations regarding the placement of a particular Part D drug on a formulary cost-sharing tier, the ultimate decision maker on such formulary design issues is the Part D plan, and that decision weighs both clinical and non-clinical factors. 4. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. Applicant will assure that the P&T committee uses appropriate scientific and economic considerations to consider utilization management activities that affect access to drugs, such as access				
answer is YES. then Applicant must complete P&T Committee Certification Statement and PBM must complete the P&T Committee Member List located in the Appendix entitled Applicant Submission of P&T Committee Member List and Certification Statement. 3. Applicant will develop and use a P&T committee to develop and review the formulary and to ensure that the formulary is appropriately review the formulary and to ensure that the formulary is appropriately review the formulary and to ensure that the formulary is appropriately review the formulary and to ensure that the formulary is appropriately review the formulary and to ensure that the formulary is appropriately review the formulary and to ensure that the formulary is appropriately review the formulary cost-sharing tier, the ultimate decision maker on such formulary cost-sharing tier, the ultimate decision maker on such formulary design issues is the Part D plan, and that decision weighs both clinical and non-clinical factors. 4. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. Applicant will assure that the P&T committee uses appr				
Member List located in the Appendix entitled Applicant Submission of P&T Committee Member List and Certification Statement. 3. Applicant will develop and use a P&T committee to develop and review the formulary and to ensure that the formulary is appropriately revised to adapt to both the number and types of drugs on the market. Note: While the P&T committee may be involved in providing recommendations regarding the placement of a particular Part D drug on a formulary cost-sharing tier, the ultimate decision maker on such formulary design issues is the Part D plan, and that decision weighs both clinical and non-clinical factors. 4. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. Applicant will assure that the P&T committee uses appropriate scientific and economic considerations to consider utilization management activities that affect access to drugs, such as access to non-formulary drugs, prior authorization, step therapy,	answer is YES, then Applicant must complete P&T Committee			
P&T Committee Member List and Certification Statement. 3. Applicant will develop and use a P&T committee to develop and review the formulary and to ensure that the formulary is appropriately revised to adapt to both the number and types of drugs on the market. Note: While the P&T committee may be involved in providing recommendations regarding the placement of a particular Part D drug on a formulary cost-sharing tier, the ultimate decision maker on such formulary design issues is the Part D plan, and that decision weighs both clinical and non-clinical factors. 4. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. Applicant will assure that the P&T committee uses appropriate scientific and economic considerations to consider utilization management activities that affect access to drugs, such as access to non-formulary drugs, prior authorization, step therapy,				
 3. Applicant will develop and use a P&T committee to develop and review the formulary and to ensure that the formulary is appropriately revised to adapt to both the number and types of drugs on the market. Note: While the P&T committee may be involved in providing recommendations regarding the placement of a particular Part D drug on a formulary cost-sharing tier, the ultimate decision maker on such formulary design issues is the Part D plan, and that decision weighs both clinical and non-clinical factors. 4. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. Applicant will assure that the P&T committee uses appropriate scientific and economic considerations to consider utilization management activities that affect access to drugs, such as access to non-formulary drugs, prior authorization, step therapy, 				
 review the formulary and to ensure that the formulary is appropriately revised to adapt to both the number and types of drugs on the market. Note: While the P&T committee may be involved in providing recommendations regarding the placement of a particular Part D drug on a formulary cost-sharing tier, the ultimate decision maker on such formulary design issues is the Part D plan, and that decision weighs both clinical and non-clinical factors. 4. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. Applicant will assure that the P&T committee uses appropriate scientific and economic considerations to consider utilization management activities that affect access to drugs, such as access to non-formulary drugs, prior authorization, step therapy, 				
 revised to adapt to both the number and types of drugs on the market. Note: While the P&T committee may be involved in providing recommendations regarding the placement of a particular Part D drug on a formulary cost-sharing tier, the ultimate decision maker on such formulary design issues is the Part D plan, and that decision weighs both clinical and non-clinical factors. 4. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. Applicant will assure that the P&T committee uses appropriate scientific and economic considerations to consider utilization management activities that affect access to drugs, such as access to non-formulary drugs, prior authorization, step therapy, 				
 Note: While the P&T committee may be involved in providing recommendations regarding the placement of a particular Part D drug on a formulary cost-sharing tier, the ultimate decision maker on such formulary design issues is the Part D plan, and that decision weighs both clinical and non-clinical factors. 4. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. Applicant will assure that the P&T committee uses appropriate scientific and economic considerations to consider utilization management activities that affect access to drugs, such as access to non-formulary drugs, prior authorization, step therapy, 	revised to adapt to both the number and types of drugs on the			
 recommendations regarding the placement of a particular Part D drug on a formulary cost-sharing tier, the ultimate decision maker on such formulary design issues is the Part D plan, and that decision weighs both clinical and non-clinical factors. 4. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. Applicant will assure that the P&T committee uses appropriate scientific and economic considerations to consider utilization management activities that affect access to drugs, such as access to non-formulary drugs, prior authorization, step therapy, 	market.			
 recommendations regarding the placement of a particular Part D drug on a formulary cost-sharing tier, the ultimate decision maker on such formulary design issues is the Part D plan, and that decision weighs both clinical and non-clinical factors. 4. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. Applicant will assure that the P&T committee uses appropriate scientific and economic considerations to consider utilization management activities that affect access to drugs, such as access to non-formulary drugs, prior authorization, step therapy, 	Note: While the P&T committee may be involved in providing			
drug on a formulary cost-sharing tier, the ultimate decision maker on such formulary design issues is the Part D plan, and that decision weighs both clinical and non-clinical factors.4. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy.5. Applicant will assure that the P&T committee uses appropriate scientific and economic considerations to consider utilization management activities that affect access to drugs, such as access to non-formulary drugs, prior authorization, step therapy,	, , ,			
decision weighs both clinical and non-clinical factors. 4. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. Applicant will assure that the P&T committee uses appropriate scientific and economic considerations to consider utilization management activities that affect access to drugs, such as access to non-formulary drugs, prior authorization, step therapy,				
 4. Applicant's P&T committee will first look at medications that are clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. Applicant will assure that the P&T committee uses appropriate scientific and economic considerations to consider utilization management activities that affect access to drugs, such as access to non-formulary drugs, prior authorization, step therapy, 				
 clinically effective. When two or more drugs have the same therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. Applicant will assure that the P&T committee uses appropriate scientific and economic considerations to consider utilization management activities that affect access to drugs, such as access to non-formulary drugs, prior authorization, step therapy, 				
therapeutic advantages in terms of safety and efficacy, the committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. 5. Applicant will assure that the P&T committee uses appropriate scientific and economic considerations to consider utilization management activities that affect access to drugs, such as access to non-formulary drugs, prior authorization, step therapy,				
committee may review economic factors that achieve appropriate, safe, and cost-effective drug therapy. 5. 5. Applicant will assure that the P&T committee uses appropriate scientific and economic considerations to consider utilization management activities that affect access to drugs, such as access to non-formulary drugs, prior authorization, step therapy,				
safe, and cost-effective drug therapy. 5. Applicant will assure that the P&T committee uses appropriate scientific and economic considerations to consider utilization management activities that affect access to drugs, such as access to non-formulary drugs, prior authorization, step therapy,				
scientific and economic considerations to consider utilization management activities that affect access to drugs, such as access to non-formulary drugs, prior authorization, step therapy,	safe, and cost-effective drug therapy.			
management activities that affect access to drugs, such as access to non-formulary drugs, prior authorization, step therapy,				
access to non-formulary drugs, prior authorization, step therapy,				
עסווסרוט פעטפענענוטרו, מרוע נורסומטכענוט ווונסוטרמרוטל טוטנטטוס.	generic substitution, and therapeutic interchange protocols.			

6.	Applicant will adhere to P&T guidelines that will, from time to time, be promulgated with regard to such subject areas as membership, conflict of interest, meeting schedule, meeting minutes, therapeutic classes, drug review and inclusion, formulary management, utilization management and review, formulary		
7.	exceptions, and educational programs for providers. Applicant's P&T committee will make a reasonable effort to review a new FDA approved drug product within 90 days, and will make a decision on each new drug product within 180 days of its release onto the market, or a clinical justification will be provided if this timeframe is not met. These timeframes also include the review of products for which new FDA indications have been approved.		
8.	Applicant's P&T committee will approve inclusion or exclusion of the therapeutic classes in the formulary on an annual basis.		
9.	The majority of the membership of the Applicant's P&T committee shall be practicing physicians and/or practicing pharmacists.		
10.	The membership of the Applicant's P&T committee will include at least one practicing physician and at least one practicing pharmacist who are both free of conflict with respect to the Applicant organization and pharmaceutical manufacturers.		
11.	The membership of the Applicant's P&T committee will include at least one practicing physician and at least one practicing pharmacist who are experts in the care of the elderly or disabled persons.		
	12. Applicant's P&T committee will recommend protocols and procedures for the timely use of and access to both formulary and non-formulary drug products.		
	13. Applicant will verify that their P&T Committee members (listed in 3.2.1 C) do not appear on the HHS Office of Inspector General's Exclusion List. This list can be found at <u>http://exclusions.oig.hhs.gov/search.html</u>		

C. If Applicant is intending for its Part D benefit to include use of a formulary, then the members of the P&T committee must be provided directly by the Applicant or by the Applicant's PBM. The membership of the P&T Committee must be comprised as described below. If Applicant is providing names of P&T Committee directly, then complete the table below in HPMS on the Contract Management/Part D Data page.

Pharmacy and Therapeutics (P&T) Committee

PROVIDE THE NAMES OF THE MEMBERS OF YOUR ORGANIZATION'S P&T COMMITTEE. INDICATE WHICH MEMBERS ARE PRACTICING PHYSICIANS, OR PRACTICING PHARMACISTS, FURTHER INDICATE WHICH MEMBERS ARE EXPERTS IN THE CARE OF

THE ELDERLY OR DISABLED, AND FREE OF ANY CONFLICT OF INTEREST WITH YOUR ORGANIZATION AND PHARMACEUTICAL MANUFACTURERS. (APPLICANTS SHOULD MARK THE INFORMATION AS PROPRIETARY.) ADD ADDITIONAL ROWS AS NECESSARY.

	Practice/Expertise Mark an 'X' in Appropriate Column			Free of Any Conflict of Interest Type Yes or No		
Full Name of	Practicing	Practicing	Elderly/Disabled	With	With	
Member	Physician	Pharmacist	Expert	Your	Pharmaceutical	
				Organization?	Manufacturers?	

Applicant Submission of P&T Committee Member List and Certification Statement

This summarizes CMS policy on Part D Applicant/Sponsor and PBM submission of P&T Committee membership, and the accountability that each Part D Applicant/Sponsor holds regarding the integrity of the P&T Committee whose membership is submitted either directly by the Part D Applicant/Sponsor or by the applicant/sponsor's PBM. This appendix also instructs Part D Applicants (or their PBM's) on how to submit the Applicant's P&T Committee membership list, and a Certification of P&T Integrity and Quality in the event the Applicant is planning to operate under a confidentiality agreement with its PBM (such that the PBM does not disclose the membership to the Applicant).

P&T Committee Member Disclosure to CMS

As provided in regulation at CFR 423.120 (b)(1), a Part D Sponsor's P&T Committee list must contain a majority of members who are practicing physicians and/or pharmacists, include at least one practicing physician and one practicing pharmacist who are experts regarding care of the elderly or disabled individuals, and includes at least one practicing physician and one practicing pharmacist who are independent and free of conflict relative to the Part D Sponsor or Plan and pharmaceutical manufacturers.

In the event the Part D Applicant/Sponsor has entered into a confidential agreement such that the PBM will not disclose its P&T Committee membership to the Part D Applicant/Sponsor, then it is the Part D Sponsor's responsibility to notify CMS that this information will be submitted by the Sponsor's PBM. Moreover, the Part D Applicant/Sponsor must ensure that the PBM notifies CMS of the P&T Committee membership. Also, the Part D Applicant/Sponsor should ensure that the PBM notifies the Sponsor that this information has been successfully submitted to CMS.

Instructions to Plans and PBMs

A. If the Part D Applicant sub-contracts with a PBM for its P&T Committee and operates under a Confidentiality Agreement (such that its members are not disclosed to the Part D Applicant) then the Applicant must (1) complete the attached Certification, and (2) forward the attached P&T Committee Member Disclosure Form to the subcontracted PBM and direct the PBM to submit the form to CMS. The PBM should follow the mailing instructions below.

B. In the event of any future changes to the membership of the Part D Sponsor's P&T Committee or the PBM's P&T Committee, Part D Sponsors must (or in the case of a confidential agreement the Part D Sponsor must assure that the PBM) notify the appropriate CMS account manager (to be assigned at a future date) within 30 days of the effective date of such change.

Mailing Instructions

1. Provide a signed cover sheet indicating that the information being sent to CMS is an addendum to the Plan's Part D Application.

 Please mail 5 CD's or diskettes containing both the completed P&T Committee Member Disclosure form and the completed Certification for Part D Sponsors Using a Pharmacy Benefit Manager's Pharmacy and Therapeutics Committee under a Confidentiality Agreement form.
 Please mail 5 hard copies, including one original, of both the completed P&T Committee Member Disclosure form and the completed Certification for Part D Sponsors Using a Pharmacy Benefit Manager's Pharmacy and Therapeutics Committee under a Confidentiality Agreement form.

Mail the 5 CD's or diskettes and hard copy material via courier to: Centers for Medicare and Medicaid Services ATTN: Eric Nevins Mail Stop: C4-21-08 Location: 7500 Security Boulevard Baltimore, MD 21244-1850

PHARMACY AND THERAPEUTICS COMMITTEE MEMBER DISCLOSURE

Name of Part D Plan or PBM:

If Part D Plan, provide Part D Contract number(s):

Contact Person:

Phone Number:

Email:

Complete the table below if a PBM submitting on behalf of Part D plan.

PROVIDE THE NAMES OF THOSE APPLICANTS FOR THE PART D BENEFIT THAT YOUR ORGANIZATION IS PROVIDING PHARMACY BENEFIT MANAGEMENT SERVICES, THE TYPE OF APPLICATION, AND THE CONTRACT NUMBER(S). ADD ADDITIONAL ROWS AS NECESSARY.

Organization Name	Type of Application	Contract Number(s)

CERTIFICATION FOR PART D SPONSORS USING A PHARMACY BENEFIT MANAGER'S PHARMACY& THERAPEUTICS COMMITTEE UNDER A CONFIDENTIALITY AGREEMENT

- A. I, the undersigned, certify, on behalf of (<u>LEGAL NAME OF PART D SPONSOR</u> <u>APPLICANT</u>) ("Applicant"), to the following:
 - I certify that APPLICANT has entered into a contract with (<u>LEGAL NAME OF</u> <u>PBM</u>) ("PBM") to perform pharmacy benefit management services related to the operation of a Medicare Part D benefit plan(s) on behalf of APPLICANT.
 - 2) I agree, to the best of my knowledge, that ("<u>PBM</u>") has a Pharmacy and Therapeutics (P&T) Committee that contains a majority of members who are practicing physicians and/or pharmacists, includes at least one practicing physician and one practicing pharmacist who are experts regarding the care of the elderly or disabled individuals, and includes at least one practicing physician and one practicing pharmacist who are independent and free of conflict relative to my plan and organization and pharmaceutical manufacturers.
 - 3) I agree that the PBM will supply to CMS the following information, including but not limited to, the full legal name of each member of its P&T Committee designated as a practicing physician or pharmacist specializing in elderly and/or disabled care. Each member must also disclose any conflict of interest with my organization, and/or pharmaceutical manufacturers.
 - I agree that my organization will establish, policies and procedures to ensure and confirm the ongoing integrity, qualifications and expertise of the PBM's P&T Committee.
 - 5) I agree that in the event CMS identifies a problem with a member of the PBM's P&T Committee, my organization will be notified by CMS of such a problem. In such an instance, my organization must assure that the PBM takes appropriate steps to correct the problem or risk being subject to a corrective action plan and sanctions, depending on the nature of the problem.
- B. I agree that CMS may inspect the records and premises of my organization or my subcontractor (first tier, downstream and related entities) to ensure compliance with the statements to which I have attested above.
- C. I certify that I am authorized to sign on behalf of the Applicant.

Part D Plan Contract Number:

Authorized Representative Name (printed)

Title

Authorized Representative Signature

Date (MM/DD/YYYY)